This may explain, at least in part, why lenalidomide shows meaningful clinical effects in MDS characterized by CK1α haploinsufficiency but lacks efficacy against AML in pre-clinical and clinical settings51. This evidence concerns the gene CSNK1A1 and myelodysplastic syndrome.